07.21.25
Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode, further exploring the value of setting expectations for patients with GA in nations without wide access to complement inhibitors. They also comment on which therapeutic approaches can be employed now and look toward possible forthcoming treatments. This podcast is part 2 of 2.
View full description +
Editorially independent content, supported by Astellas
Subscribe
09.04.25
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDRDavid Lally, MD; and Ehsan Rahimy, MD
Editorially independent content, supported by Genentech
08.21.25
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human GradersJohn Kitchens, MD; Krishna Mukkamala, MD
Editorially independent content, supported by Genentech
07.21.25
The State of Geographic Atrophy Around the Globe: Part 2 of 2Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD
Editorially independent content, supported by Astellas
07.21.25
The State of Geographic Atrophy Around the Globe: Part 1 of 2Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD
Editorially independent content, supported by Astellas
07.18.25
Diabetic Retinopathy Severity and Income StatusBen Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD
Editorially Independent Supported By Genentech and Neurotech.
07.07.25
GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing TherapyJudy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD
Editorially independent content, supported by Apellis
07.07.25
GA in 2025: Dosing Regimens, Drug Selection, and Ideal CandidatesJudy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD
Editorially independent content, supported by Apellis
Show More